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Summary  
The health sector and medical technologies are of an increasing importance in society and for 
regional and national economies. Much like other life sciences industries, the medical devices 
sector relies upon specific factors and knowledge processes that shape and support its 
innovation capabilities and competitiveness. Previous studies have shown that growth and 
innovation in this sector depend on specific local factors and conditions as well as on markets 
and knowledge-interdependencies at higher spatial scales. There is still a research gap on the 
detailed nature of these driving factors and relationships, however. In this research, we have 
investigated these issues for the Vienna medical devices cluster that is part of the wider life 
sciences sector in this region. The main aims of the study were to generate insights into how 
different economic, knowledge- and policy conditions, and their spatial scales, interact to 
support and hinder development of the medical devices industry in Vienna, and to draw policy 
conclusions based on these findings.  
 
The first stage of the study involved a literature review to factors and processes supporting 
medical cluster growth, and to medical devices innovation and related knowledge flows. The 
literature review also included a survey of contextual materials (such as reports and secondary 
data sources) on the medical devices industry in Vienna and in Austria, focusing on aspects of 
its history, size, structure and growth. The primary data collection on driving factors, 
knowledge bases, and policies of the Vienna medical devices cluster was carried out based on 
interviews with eight industry experts and with an interview survey of 30 firms. This analysis 
provided novel insights into, first, the importance of local, national and international factors 
for innovation and competitiveness of this sector in Vienna, second, knowledge processes and 
–interactions inside and outside the firm, and the policy- and governance environment. 
 
The Vienna medical devices cluster is based on a long tradition in Medical science, 
engineering and precision mechanics in the region. Companies located there have some older 
roots, but most of them have been set up since the 1970s. One third of all Austrian medical 
devices firms are nowadays located in this region. R&D performing firms are specialised e.g. 
in software for medicine, telemedicine and e-health, electromechanical medical devices, 
dental technology, diagnostic and therapeutic devices, and surgical instruments, but there is a 
high heterogeneity of firms. In order to take this into account we distinguished between four 
groups. Group A firms are engaged in non-invasive high-tech medical devices, Group B in 
invasive high-tech products, Group C in low-tech devices, and Group D only sell and 
distribute medical devices products to the Austrian and nearby market. Both the high-tech and 
low-tech firms are highly specialised, and employ highly qualified people. The technology 
intensive Group A and B firms engage more in R&D and innovation, and they show a more 
steady growth. They also sell more internationally than the rest, and they are better networked 
at an international scale. Group C firms are in low-tech medical devices, they tend to be older, 
and they rely more on regional and national networks for knowledge flows and innovation. 
These firms face price-based competition from international markets and they show slower 
growth. Group D firms are sales- and distribution firms, often subsidiaries of global firms, 
specialised in selling to the Austrian and nearby CEE market. Overall, the main strengths of 
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the sector are incremental innovation, local and national networks, and an understanding of 
the domestic market. Firms invest many resources also in meeting international regulatory 
environments for their products, which differ greatly across countries. The sector benefits 
from a growing domestic and foreign demand, and research collaborations mainly with local 
and Austrian universities.  
 
The medical device sector in Vienna also has some weaknesses and challenges to overcome 
for maintaining its competitiveness. The R&D that the firms engage in does not yield the 
growth rates of other technology-based sectors in Austria. International networks are scarce 
and recent, and often lack a strategic orientation. International competition in the domestic 
market is rising. A further important challenge is increasing international regulation and 
marketing, which is becoming more complex to oversee and manage. Policy actors both on 
local and national levels should address these challenges facing the medical devices sector in 
Vienna and the country.  
 
We arrive at the following policy conclusions for improving the competitiveness and 
performance of the medical devices cluster in Vienna. The knowledge bases and innovation 
capabilities of local firms need to be further strengthened. In this context, not just radical but 
also incremental innovation should be supported and enhanced in the sector and related 
technology areas. For this purpose, the domestic knowledge- and skills base should be 
strengthened through investment into schools, colleges and universities, and through 
recruitment of expertise from abroad. Local connections to hospitals, doctors and the broader 
healthcare sector in product development and testing, as well as international networks need 
to be deepened and broadened. Furthermore, a good understanding of and experience in 
meeting international regulatory settings for medical devices products is crucial.    
 
  
7 
 
1. Introduction 
 
Globalisation processes such as enhanced international trade and -competition, transnational 
firms and production relocation, and the associated challenges to employment, have 
transformed regional growth environments. Metropolitan regions such as Vienna are forced to 
adjust their development strategies in order to maintain the competitiveness and dynamics of 
their industries, and to foster new trajectories for job creation. In order to respond to such 
challenges, governments have placed particular importance on potentially highly profitable 
industries that might create high-paying jobs (Porter, 2000; OECD, 2014). Knowledge and 
technology intensive industries, such as information communication technologies (ICTs), new 
media, and life sciences including medical devices were explicitly targeted e.g. through 
cluster- and innovation policies. These sectors are engaging in processes of knowledge 
creation that differ by their respective knowledge bases (for example, analytic, symbolic or 
synthetic knowledge) and the processes of knowledge sourcing and its integration into firm-, 
product- and service functions (Pouder and St John, 1996; Cooke, 2002; Asheim and Gertler, 
2005).  
 
Several studies have identified Vienna as a centre for medical activities, possessing high 
levels of competencies in areas such as pharma-biotech, prosthetics and imaging (LISA 
Vienna, 2014; Hochgatterer et al., 2014). Vienna’s medical cluster benefits from world-
leading research hospitals, a developing life sciences sector (Trippl and Tödtling 2007), and a 
small but growing medical devices and digital imaging sector. Overall, the sector is of 
considerable importance for innovation, growth and healthcare provision for the population in 
the region and beyond (Tödtling and Trippl, 2013). Moreover, since the early 2000s the life 
sciences- and medical devices sectors have been central pillars of Vienna’s science, 
technology and innovation (STI) policy (Stadt Wien, 2004; ZIT, 2013; 
www.wiendenktzukunft.at, www.wienwin.at) and a major focus of large-scale funding 
programmes for enhancing the quality of life of citizens such as the Ambient Assisted Living 
Programme (BMWF et al., 2013). In addition to direct economic benefits for employment, 
sales, firm formation and economic growth, the Vienna medical cluster has substantial direct 
importance for the local population in meeting changing healthcare requirements of the 
elderly and increasing complexity of diseases that such demographic changes bring about.  
 
While the biotechnology sector in Vienna has been well researched in the past (Trippl and 
Tödtling, 2007; 2008), there is less understanding of innovation dynamics in the broader 
medical devices cluster, that employs the same amount of people as the pharma-biotech 
cluster (see LISA Vienna, 2015). This has justified the enquiry of this study. It aims at a better 
understanding of the importance of and diversity in knowledge bases and knowledge flows 
that characterise the innovation processes in the Vienna medical devices cluster, and to inform 
and improve regional-policy making. In order to fulfil this aim and address the empirical gap, 
the research has been guided by the following questions: 
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• Which factors and processes were important for the development of the medical 
devices sector in Vienna? 
• What are the knowledge bases and –sources of the Vienna medical cluster?  
How are firms using and combining different kinds of knowledge in order to innovate? 
• What are the barriers and supports to innovation, upgrading and cluster growth?  
  
In order to answer these questions, we undertook a review of theoretical and empirical 
literature, and collected and analysed secondary and primary data. The following section 2 
presents a literature review of some of the main approaches to medical devices innovation and 
clustering, also highlighting the knowledge types and spatial dimensions of relevant factors 
and interactions. Section 3 gives a background to the medical devices industry in Vienna. We 
describe the beginnings of the local industry as well as the changes in its size, composition 
and structure, and some of the significant events that have influenced cluster formation and 
growth. This section relies on secondary data sources, such as the AURELIA database and the 
LISA Vienna Region database. In section 4 the results of the empirical survey addressing 
factors for the development of firms and the cluster, are presented. Using both quantitative 
and qualitative data collected in the interview survey of 30 medical devices firms in Vienna 
and eight industry experts, this chapter presents regional, national and international factors for 
the development of various types of medical devices firms in Vienna. Section 5 highlights 
empirical results for the knowledge- and innovation processes of the Vienna medical devices 
cluster dealing with internal competencies as well as external sources of knowledge such as 
collaborations at different spatial scales. Section 6 describes the governance- and policy 
context of the medical device sector in Vienna. The central institutions that formulate and 
implement policies for the sector are described, with a special focus on those that influence 
innovation and growth prospects of the firms. The chapter relies upon a review of grey 
literature and documents, as well as the expert and company interviews mentioned above. 
Finally, section 7 concludes with policy suggestions for strengthening the medical devices 
sector in the region. 
 
2. Literature review  
 
The following section presents some of the main features of innovation in medical devices, to 
highlight the characteristics of knowledge processes and innovation in this sector. Second, we 
review the main empirical studies examining the spatial dimension of the medical devices 
sector development and its clustering are. The third body of literature links medical 
innovation to types of knowledge bases and -flows, and provides the theoretical rationale for 
the study.  
 
2.1 Medical devices innovation 
Invention- and innovation processes in medical devices have been the subject of much 
scholarly work from the disciplines of medicine, history, economics and sociology. Here we 
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briefly review some of the main aspects highlighted by historians, economists and sociologists 
of technological change, focusing on the role of knowledge in medical devices innovation. 
The medical devices sector has been associated with a large quantity of innovations with the 
potential for the advancement of human health, wellbeing, and increase in life expectancy 
(Jennett, 1986; Pickstone, 1992; OECD 2008). Products are highly diverse, ranging from 
“high-technology” devices such as sophisticated surgical and medical instruments to “low-
technology” devices such as hospital beds, wheelchairs, bandages, syringes and glasses (De 
Vet and Scott, 1992:146). Within these product categories we find a large technological 
diversity. High-technology medical devices include products such as computed tomography 
(CT) scanners that combine technologies such as X-rays with data processing power of 
computers, and magnetic resonance imaging (MRI) machines relying upon signals created by 
magnetic waves and their interpretation by computers (Gelijns and Rosenberg, 1999), as well 
as rapidly improving high-end visualisation software. Following Pickstone (1992), Metcalfe 
et al. (2005), Metcalfe and Pickstone (2006), the knowledge developed and used in medical 
innovation is inseparable from scientific developments, progress in other technological areas 
and the techniques with which it is applied (von Hippel, 1988). Contrary to innovations in the 
pharma-biotech fields, medical devices and their improvements have often been outcomes of 
discoveries in physics and engineering (Rosenberg, 2009).  
 
Many scholars have shown that medical innovation is influenced by accumulation of 
knowledge through interactions of diverse actors and organisations such as firms, hospitals 
and healthcare providers (including research-minded doctors, user technicians, and patients), 
and medical research universities (Hippel, 1988; Metcalfe and Pickstone, 2006; Webster, 
2006). Detailed histories of innovation in medical devices reveal its slow and incremental 
nature (Metcalfe et al., 2005) with slight modifications that do not normally reflect new 
knowledge (Rosenberg, 2009). In some areas such as prosthetics and orthotics, products such 
as artificial hips have emerged as relatively simple devices that gradually became more 
complex as they were combined with different technologies over time (Metcalfe and 
Pickstone, 2006).  
 
Further important aspects of medical innovation are the industry- and market structure. The 
medical device industry is composed of several smaller industries that contribute to a variety 
of technology areas and a broad range of products. The diagnostic imaging devices industry is 
dominated by few very large firms, such as Siemens, Philips, Toshiba and General Electric 
(Gelijns and Rosenberg, 1999). The rapidly growing small instruments industry (such as for 
example cardiovascular devices, glucose monitors, and insulin delivery devices) is dominated 
by the US players Johnson & Johnson, Boston Scientific, Abbott, Medtronic and others 
(Chatterji, 2009). The larger firms in these industries tend to behave much like manufacturing 
firms, focusing on incrementally improving their existing products (such as Siemens, Toshiba 
and GE in developing the next generation CT scanner). The smaller firms rather invest in 
developing radically different products, to be patented and licensed to other firms or to 
healthcare providers. 
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In their study of the national competitiveness of the medical diagnostic devices industry, 
Gelijns and Rosenberg (1999) find three main dimensions of the national innovation system 
that strongly influence competitiveness: the science base, intellectual property rights, and 
features of the national healthcare system. Universities, especially physicists and engineers in 
European and US universities played an important role in some of the major developments in 
medical devices technology areas. However, unlike pharma-biotech, which is highly 
dependent upon scientific research conducted in universities, much research for medical 
devices occurred in firms. There is a higher dependency on medical universities and hospitals, 
which are important for delivering ideas and for testing devices.  National healthcare systems 
have different regulations and these can significantly affect the processes by which medical 
innovation and industry growth can occur. The degree to which a medical specialisation is 
prevalent in a country co-determines the demand for the devices (Gelijns and Rosenberg, 
1999). Healthcare systems also differ in how they are financed (publicly, as in Germany, UK 
and other European countries, or privately, as in the US) and how various products and 
product classes are regulated. In a privately financed and less regulated system such as in the 
US, the demand for many types of medical devices is higher and they are easier to sell. In 
publicly funded systems, procurement and reimbursement policies can determine whether a 
product is sold or not. In a sector where testing and reputation is very important, the home 
market can be crucial in the early stages of product development (Gelijns and Rosenberg, 
1999). 
 
2.2 Clustering in the medical devices sector – A view from the literature 
In addition to national advantages, some cities and regions have a specific science- and 
knowledge base, infrastructure, organisations, and social and institutional cultures (Boschma, 
2005) that make them superior to other localities for particular sectors and firms (Saxenian 
1994, Keeble and Wilkinson 2000). Medical devices firms sometimes exhibit clustering 
behaviour for reasons such as the existence of key organisations and institutions in a 
particular location. Large R&D intensive firms can be key organisations for exploiting 
knowledge from local universities and for anchoring an industry in a region (Feldman et al. 
2005). Individual work experience in large firms may be essential for gaining knowledge and 
skills and professional networks for setting up new firms. The existence of organisations such 
as venture capital firms are further important location- and innovation factors, especially for 
sectors such as life sciences (Powell et al., 2002). Universities, university hospitals, and the 
broader institutional advantages of regions such as Cambridge UK and Boston, foster 
conditions and an entrepreneurial culture in which it is easier to set up new medical devices 
firms than in other regions (Feldman et al., 2005; Garnsey and Heffernan, 2005).  
 
In their 1991 study on the US, Jan de Vet and Scott identify medical clusters in five states: 
California, Florida, Illinois, Massachusetts and New York, with the biggest concentration of 
medical devices firms in Southern California. Their study traces the development of the 
Southern Californian cluster and highlights important events that shaped its successful 
trajectory. The cluster partially emerged from the entry of several important actors in the 
region in the 1950s, such as a manufacturing firm specialised in aerospace electronics, a 
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hospital supply firm, and the opening of an airport. These attracted other aerospace electronics 
firms to the region, some of which expanded into medical devices because of similarity in 
techniques (Jan de Vet and Scott, 1991:150). In the 1970s the cluster saw a series of spin-offs 
from a large research and biomedical firm, and has continued to grow ever since. The labour 
pool of experienced engineers and managers in the locality made it easier for spin-offs to 
grow, through hires and direct contacts. The diverse labour pool (and the related knowledge 
and skills) benefits the firms because of the partially unpredictable knowledge requirements 
of innovation in this sector. Formal contacts to universities were frequent, and over 90% of 
the firms have patented innovations. Venture capital has been very important, especially for 
the high-end segment of the industry. 
 
In his more recent study of the US medical devices industry Chatterji (2009) finds that 
academic research and patenting are very important, indicating an increase in the importance 
of scientific knowledge for the industry over time (p. 189). Doctors acted as key innovators, 
and their ideas were relevant for new firm formation. Moreover, venture capital has been very 
important, taking over 700 million US dollars in 2004. Experience in large firms was very 
useful for spin-off founders, as well as multiple experiences in starting firms. Other people 
who founded firms were serial entrepreneurs, doctors, or outsiders to the industry. Those 
firms founded by people who used to work in the larger companies performed better than 
other ventures, but based on patent citation analyses, they did not rely upon the technical 
knowledge from the parent firm. Rather nontechnical knowledge has been more relevant, 
including regulatory knowledge, marketing knowledge (how to market to doctors) and how to 
identify new market opportunities in medical devices, all of which were said to be more 
important than technical knowledge for spin-off success.  
 
According to the Warwick Institute for Employment Research (2004) report on medical 
devices clusters, some of the most advanced medical clusters in the world are located in the 
West Midlands and in Scotland (United Kingdom), in Baden-Wuerttemberg and Bavaria 
(Germany), in Medicon Valley (Denmark and Sweden), and in Massachusetts (USA). The 
study compares and contrasts the six clusters based on their institutional arrangements for 
skills training and provision for the medical devices clusters. It finds that all medical 
technology clusters are dependent upon a high skill input. The most important skill types were 
related to R&D, such as scientists and engineers. Other important competencies are those 
associated with production (management and production line) and in strategy (strategic vision 
and marketing). The specialisations of the clusters studied have roots in their industrial 
histories. Regional policies in relation to the clusters were found to be important, as well as 
close links between local research institutions and medical technology firms (especially in 
Germany and in the US). The study concludes that medical technologies industries possess an 
enormous growth potential with a high capacity to generate high skill and high wage 
employment, perhaps more so than most other manufacturing sectors.  
 
In the study of Toronto’s life sciences industries, Lowe and Gertler (2009) go beyond the 
listing of supporting factors such as research universities, commercialisation systems, venture 
capital, recruitment of ‘star scientists’, and experienced managers and entrepreneurs. They 
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argue that such a listing ignores important roles played by institutions for the development of 
clusters. Using the case study of Toronto, the authors find that the region receives the most 
funds for medical research for Canada, but also shapes the regulations for drug pricing by the 
government. Further important features are the ways in which local hospitals procure 
products, the demand for research support by the local generic drug makers, and the diversity 
of life sciences research that “encourages experimentation across disciplinary boundaries” 
(ibid. p. 596). They find evidence of frequent consumption of local products as well as of 
centralised procurement offices and inter-hospital buying ‘clubs’ who give contracts to high-
volume multinationals such as GE, Baxter, Johnson & Johnson and Medtronic (ibid. p. 597). 
The interviews they carried out suggest that specialty- and customized products are purchased 
via front-line practitioners and division administrators, giving rise to a kind of ‘bifurcated’ 
purchasing system (ibid. p. 597). The medical practitioners, who set up their own companies 
in the region, said that they used their previous professional networks in the hospital system to 
distribute their products. There is also a high concentration of generic drug development 
firms, the highest in the country. Venture capital in the region has long favoured core 
biotechnology over medical devices firms.  
 
2.3 Knowledge bases and multi-level sources of knowledge 
Industries differ according to the characteristics of their predominant knowledge bases 
By providing a frame to differentiate between the modes and structures of knowledge 
accumulation the knowledge base approach is a complementary view to how knowledge is 
adopted, generated and applied in organisations, regions and sectors (Manniche, 2012).  
Asheim and Gertler (2005) characterise knowledge bases of individual industries as a key 
feature underlying innovation. The typology is composed of analytic, synthetic and symbolic 
(SAS) knowledge bases. The analytic knowledge base represents industries that 
predominantly rely upon scientific advancements for innovation processes, such as the 
biotechnology industry (Gertler and Wolfe, 2006). The processes by which knowledge in 
these industries is derived involve deductive reasoning and formal modelling, mainly carried 
out in R&D labs of firms or universities. Academic spin-offs therefore are a frequent 
phenomenon. Knowledge tends to be codified and, relative to tacit knowledge, more easily 
transferred. The individual skills that these firms rely upon are analytical skills, abilities to 
think abstractly, to build theories and test them, as well as the documentation of research in 
reports and scientific publications (Plum and Hassink, 2011). Industries characterised by a 
synthetic knowledge base tend to combine existing knowledge, such as is the case 
predominantly in many manufacturing industries. Knowledge combination in these industries 
occurs through interactions between firms, clients and suppliers. Innovation here relies upon 
inductive reasoning and problem solving, and activities focus on development (rather than 
research) such as “system design, prototyping, fine-tuning, testing and practical work” (Plum 
and Hassink, 2011:1144). Tacit knowledge plays an important role in knowledge creation 
through practice and problem solving typical for these industries. Skills are acquired on the 
job, or through apprenticeships and polytechnic colleges (Plum and Hassink, 2011:1144). The 
symbolic knowledge base supports the aesthetics, design and the “economic use of various 
forms of cultural artefacts” (Asheim, 2007:226). The importance of this knowledge base is 
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reflected in the importance of design in successful products, and the increase in the role of 
creative industries in the economy. The activities associated with the symbolic knowledge 
base are about new ideas, images, appearance and symbols that rely upon interpretation rather 
than production (Asheim, 2007:226). Symbolic knowledge is strongly connected to the 
understanding of social norms and ‘everyday culture’ of social groups and is therefore highly 
tacit (Asheim, 2007:226; Martin and Moodysson, 2011). The skills for creativity in design are 
acquired through practice and learning-by-doing, rather than through formal training. Creative 
industries tend to work in projects that tend to be limited in time. It is more efficient to rely 
upon social and professional networks to carry out the individual tasks, rather than to have all 
people in-house. In practice all industries will rely upon several knowledge bases (Asheim, 
2007:226), but the degree to which they do will differ, putting them at different points on the 
spectrum of the individual knowledge types. Some empirical studies have suggested that it is 
the combination between knowledge bases, rather than singular rooting within them that 
characterise innovation in clusters (Strambach and Klement, 2012; Tödtling and Grillitsch, 
2015).  
 
Complementing the SAS literature, Strambach and Klement (2012) offer two further 
dimensions that are helpful in highlighting how and why certain sectors innovate and grow 
more in some regions than in others. These authors emphasise the cumulativeness of 
knowledge in industries and draw on institutional theory in innovation studies to emphasise 
the co-evolutionary nature of learning and socio-cultural processes. They offer a distinction 
between sectors that rely predominantly on cumulative processes (such as tourism) and 
sectors that combine different types of knowledge at the micro level (such as new media; 
Strambach and Klement, 2012:1855). Cumulative knowledge bases are incrementally 
adjusting knowledge in a path-dependent way, whereas combinatorial knowledge is a mode of 
creating links and components of previously (regionally) disconnected knowledge types. 
Industries draw on combinations of knowledge types (SAS), and combine them to different 
intensities. For example, the biotechnology and the ICTs sectors tend to put a lot of effort in 
combining different knowledge types. Strambach and Klement (2012) and Manniche (2012) 
state that the SAS approach is perhaps more suited in studying micro-level knowledge 
dynamics which may more readily fit individual knowledge base types, but that at higher 
levels of aggregation such as regions and sectors it becomes more likely that we find 
combinations of knowledge bases. 
 
Knowledge flows occur at different spatial levels 
A second hypothesis extending the knowledge base approach is that knowledge flows in and 
out of clusters at different spatial levels, from local to global ones (Asheim et al., 2011; 
Tödtling et al., 2013). The argument is that the territorial dimension of knowledge relations 
and their multilevel character matters for learning and innovation in clusters. Whereas 
geographical and institutional proximities at the local and regional levels support the 
exchange of tacit knowledge and interactive learning, selective knowledge links with firms 
and research organisations at the international and global levels contribute complementary 
and specialised, often codified, knowledge assets (Bathelt et al., 2004).  Innovative cluster 
firms tend to be both well embedded in the regional innovation system and well connected to 
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partners and networks of production, distribution, R&D, and knowledge exchange at 
international and global levels (Archibugi and Lundvall, 2001; Powell and Grodal, 2005). 
Accordingly, recent studies have pointed to the multi-level and multi-scalar nature of 
knowledge relations in the innovation process (Asheim et al. 2011, Tödtling et al., 2013). 
Indeed, Strambach and Klement (2012) state … “it is rare that innovation dynamics unfold on 
one spatial scale” (p. 1851).  
 
Some aspects of knowledge- and learning processes are highly localised (i.e. embedded in 
local, regional and national institutional settings), such as social norms, legal frameworks, and 
the capabilities of firms and organisations that are located there. This idea and argument was 
inspired by the national innovation systems concept (Edquist (1997, Lundvall 2007), where 
innovation has been conceptualised as based on interactions between firms, universities, 
governmental and non-governmental agencies, governed by an institutional framework that is 
specific to a national context. Furthermore, a regional innovation system (RIS) was said to 
exist when institutions support and interact with the industries in a region (Cooke et al., 
2000). In particular, in federal countries the regional level acts as a meso-level that supports 
economic coordination through decentralised governance structures (Cooke et al., 2004). 
Other studies have emphasised the role of global processes such as market- and technological 
changes, R&D collaboration, and FDI. More recent research has highlighted the importance 
of interactions between local and global processes (Bathelt et al. 2004), and shifts of scales 
over time as the local cluster evolves (Menzel and Fornahl, 2009).  
 
Plum and Hassink (2011) in their study on the Aachen biotechnology cluster refer to the role 
of nationally and globally distributed knowledge networks. The advantages of physical 
proximity and closeness at regional and national levels are associated with lower cognitive 
distance, ease of communication provided by opportunities for face-to-face interaction and a 
common language, and potentially higher levels of trust. These aspects can make innovation 
processes between firms and other organisations closely located to one another easier, such as 
in regional innovation systems or in clusters. However, the competitiveness of clusters also 
often depends on the quality of their connections to global actors and networks.  
 
Asheim and Coenen (2007) analyse how industries differ on the extent and degree to which 
they rely upon different knowledge bases and therefore types of knowledge. Also the 
mechanisms of knowledge transfer (such as face to face and buzz) vary by industries. The 
buzz concept highlights the importance of know-who in creative work, since it is important to 
know which individuals are good at what in order to be successful. Buzz refers to rumours, 
impressions, recommendations and strategic information that tend to be local and more 
important in symbolic industries. Furthermore, symbolic knowledge relates to an aesthetic 
quality of products, tied to an understanding of everyday culture of social groups because of 
the cultural embeddedness of interpretation, thus making the local context for knowledge 
exchange highly important.  
 
Face-to-face communication is also important for synthetic knowledge base industries 
because of the partly tacit nature of this knowledge. Inspiration for new products and 
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techniques comes from problems experiences of customers, which are revealed through 
personal contact. According to Martin and Moodysson (2011), however, the synthetic 
knowledge-based industries rely both on regional and global knowledge as well as on tacit 
and codified knowledge. Engineering- and applied knowledge is more important for them 
than science based knowledge, so spatially proximate firms and users are important network 
partners, as Plum and Hassink (2012) argue in their analysis of a German automotive cluster. 
Even though the authors underlie the contextual specificity as a hinderance to making analytic 
generalisation (Plum and Hassink, 2012:223), we assume that these processes will be similar 
to other synthetic knowledge based industries.  
 
For the medical devices sector it can be summarised that the innovation process differs from 
the one in other medical fields (such as pharma-biotech), in that it relies relatively more on 
practical knowledge and know how (i.e. synthetic knowledge base) than on scientific 
knowledge (i.e. an analytical knowledge base). Competencies inside the firm as well as 
interactions between firms and users play a bigger role for innovation than knowledge 
produced in cooperation with universities. Furthermore, the need to combine knowledge from 
different fields makes combinatorial capabilities of firms important. Further relevant factors 
are the local skills base (quantity as well as diversity in qualifications, skills and experience), 
and proximity to hospitals, medical institutions and users.   
 
3. Medical sector context, method and firm overview 
This section first characterises the medical devices sector in Vienna dealing with its size and 
structure, and relates to regional innovation system features. In the second part, we describe 
the method and firm sample characteristics, which sets the scene for analysing factors for 
growth and innovation in sections 4 and 5. 
 
3.1 Medical devices sector and growth 
Vienna is the main centre for medical activities in Austria and possesses competencies in 
areas such as pharma-biotech, prosthetics and imaging (LISA Vienna, 2014; Hochgatterer et 
al., 2014). The Vienna medical devices industry is based on a long and centuries old tradition 
in Medical science, engineering and precision mechanics.1 One third of all Austrian medical 
devices firms are located in this region (33 out of 98 firms) (LISA Vienna, 2015). LISA 
Vienna classifies medical technology firms in ‘dedicated’ medical technology firms (domestic 
firms performing R&D) and ‘active’ medical technology firms (domestic producing firms). 
The main firms performing R&D are specialised in software for medicine, telemedicine and 
e-health, electromechanical medical devices, consumables, dental technology, diagnostic and 
therapeutic radiation technologies, reusable and surgical instruments, and technical aids for 
invalids. The average age of the companies is 18 years and the cluster can be considered, on 
                                                 
1 We characterise the life sciences cluster Vienna as having two main industry components: the medical 
technology industry specialised in medical devices, and the pharma-biotechnology industry specialised in drugs. 
In this research project, we focus on the first, building on previous work by Franz Tödtling and his colleagues on 
the biotechnology and ICTs clusters in Vienna and in Austria. 
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the one hand, as maturing and on the other as growing especially through the accumulation of 
IT capabilities. More than half of the firms in this industry have been set up in the last 10 to 
15 years. In contrast to biotechnology, medical devices have shorter development times and a 
lower development risk, generating on average four times the revenue invested in R&D. The 
firms are mainly small, employing less than 10 people, and highly specialised. Table 1 below 
shows the 30 firms by year of foundation, demonstrating that the majority of the firms were 
founded after the 1970s, with a notable increase in foundations in the 1990s and 2000s, 
indicating an emerging industrial specialisation for Vienna.  
 
Figure 1: Vienna medical devices firms by year of foundation 
Source: Authors’ own elaboration based on AURELIA database  
The Vienna city region and its innovation system have the highest concentration of 
specialised and teaching hospitals in Austria, and hosts one of the two main medical and 
technical university centres in the country (the second is in Innsbruck). The city is the location 
of the largest hospital in Europe (the General Hospital, or AKH), which is engaged also in 
teaching and research, in addition to a number of smaller and specialised hospitals. Vienna 
also has a medical university and a technical university, both of which are important for 
training medical practitioners, scientists and engineers in Austria. These health and other 
organisations act both as powerful clients and as providers of various kinds of knowledge for 
the medical devices sector. The large variety of organisations and institutions in large and 
capital cities such as Vienna imply that their clusters exhibit characteristics of both 
specialisation and diversity (Huallachain and Lee, 2011). Furthermore, the social, economic 
and cultural proximities of Austria to German and Swiss markets (also known as the “DACH” 
region) are significant for R&D and production channels for many sectors in Austria, and also 
for this sector. One of the largest R&D firms in medical devices in Vienna is a R&D 
subsidiary of the German Otto Bock Healthcare Products, specialised in prosthetics.  
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3.2 Method and firm sample 
We surveyed 30 firms2 in total, 25 of which were innovation-active, and 5 of which were 
trading and resale firms3. We included both Austrian-owned and foreign-owned firms in the 
sample. We selected firms by using the AURELIA Database, a comprehensive firm database 
for Austria, as well as the LISA Vienna data, showing a detailed listing of medical devices 
firms in Vienna and their characteristics. We interviewed general managers of the firms from 
one to four hours. The interview schedule focused on the following topics: (1) general firm 
characteristics, (2) history and development of the firm, and (3) of the medical devices cluster 
in Vienna, (4) firm innovation activities, (5) firm cooperation and knowledge relations, (6) 
financing and business model, (7) role of policy, and (8) expectations, challenges and need for 
action. Before carrying out the firm survey, we got first-hand background information with 
six open-ended exploratory interviews with persons experienced in the medical devices sector 
in Vienna (business- and research consultants, policy-actor, university-technology-transfer 
office, and an intermediary between government and industry). The quantitative data was 
analysed with descriptive statistics using SPSS for Windows and Windows Excel. Qualitative 
data were analysed by coding them relying on concepts of the theoretical frame, and in a 
second step drawing analytic conclusions based on relations and interpretations from the 
analysis.  
 
The following potential biases and problems may have affected our sample and results. The 
selection of “innovation active” firms (in 2015) is static, and ignores the possibility that some 
firms may have invested in innovation in the past or intend to do so in future. Most of our 
sample firms were founded after the 2nd World War (with the majority founded after 1970), 
which can be taken as a reasonable long period of time to investigate growth- and innovation 
conditions for this sector in Vienna. However, asking people questions about the past is 
always tricky, because they may not remember things accurately, or at all. We tried therefore 
to corroborate with grey literature on the medical devices industry in Austria and Vienna. Our 
interviews, thus, dealt with both objectively quantifiable data that we were able to check with 
other sources (such as year of foundation and changes in the number of employees over time) 
and subjective data (such as the importance of specific skills for company- and cluster 
development). It was, therefore, essential to pose questions in different ways and to allow 
respondents to talk freely. Still we need to interpret the results with great care.   
 
Data for the whole sector, such as depicted in Figure 1, are important in understanding general 
patterns. Aggregations however hide possible difference across technology areas, such as 
ICTs and fine mechanics, and important insights might get lost. For the purpose of 
differentiation, we follow therefore scholars of the medical devices sector investigating the 
innovation process. Gelijns and Rosenberg (1999:313) suggested distinguishing between 
firms in the diagnostic devices industry according to the non-invasive (not inserted under the 
                                                 
2 We are grateful to Lorenz Stör for his help with the firm interviews.  
3 Trade and sale firms usually do not innovate. They were, therefore excluded from the analysis in some sub-
sections. The reason for including some of them in our survey is that sales and distribution firms make up the 
majority of medical firms in Vienna (over 90%) and we wanted to obtain insights also into this important part of 
the sector. 
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skin or inside the body) and invasive nature of products (inserted under the skin or attached to 
the body). De Vet and Scott (1992) in their analysis of medical devices industries in the 
United States, differentiate between high-tech and low-tech firms. Based on a first analysis of 
our data, we combine the distinctions used in these two studies, and categorise our sample in 
four main groups: high-tech non-invasive diagnostics and monitoring devices (Group A), 
high-tech invasive prosthetics, mechanical and robotic devices (Group B), low-tech products 
(Group C), and medical devices distribution and sales firms (Group D). We describe some of 
the basic features of the four groups below. The analyses carried out in the remainder of this 
section use the groups as a lens to compare and contrast the main factors underpinning firm 
and cluster development in the medical devices industry in Vienna.  
 
Group A: High-tech non-invasive diagnostics and monitoring devices 
Group A firms (11 out of 30) are active in the rapidly evolving technological areas of 
diagnostics and monitoring devices for healthcare that are non-invasive. The firms in this 
group produce and sell digital electrical imaging products and applications for monitoring and 
diagnosing skin surface and inner body changes (for example, skin injuries and changes in 
tumours) and IT systems for data and logistics for healthcare organisations. Most of these 
firms are originally IT firms or have re-specialised to software engineering and information 
requirements of the healthcare sector, or were originally electronics firms that have diversified 
into non-invasive diagnostic devices for healthcare applications.  
 
Group B: High-tech invasive prosthetics, mechanical and robotic devices  
Group B (nine out of 30) is composed of firms that produce invasive medical devices in the 
areas of dentistry, cardiology, prosthetics and ophthalmology devices. Strictly speaking, not 
all products in Group B are equally invasive. Prosthetic limbs, for example, are typically 
attached to rather than inserted into the body. The products include dentistry products for jaw 
operations and implants, and ophthalmology products and services for treatment of eye 
diseases and eye surgery, and cardiology devices for healing of the heart tissue after a heart 
attack among others. This group also contains Otto Bock Healthcare Products, a relatively 
large, innovative and internationally competitive subsidiary performing R&D in Vienna. In 
terms of innovation interactions, it is a potential regional anchor for the medical devices 
sector.  
 
Group C: Low-tech products 
Group C firms (five out of 30) innovate at the ‘lower’ end of the technological complexity 
spectrum. These firms sell products that can be invasive (for example surgical instruments 
such as knives and syringes, artificial eyes) or non-invasive (such as bandages and disposable 
materials and textiles for hospitals). This group has the oldest medical devices firms in 
Vienna, and includes firms specializing in bandages and surgical knives among others. Most 
of the production of such products has moved to countries where labour is cheaper (for 
example, Pakistan for the manufacturing of surgical knives), and many firms that had 
previously been active in these product areas have gone out of business because of price 
competition from abroad (for example, from China). Together, Groups A, B and C make up 
over 90% of all medical devices firms in Vienna that perform R&D.  
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Group D: Medical devices distribution and sales firms 
Group D are trading firms (five out of 30) who at the time of interviewing and in the previous 
three to five years did not carry out any R&D or production in their location in Vienna or 
Austria. In the overall population of medical devices firms in Vienna, this group of firms is 
the largest, making up over 90% of all firms in this sector4. These firms are mostly 
subsidiaries of multinationals that have been placed in Vienna to cover the Austrian 
healthcare market (or, in some cases, the Eastern European market). The five distribution and 
sales firms in the sample have their headquarters in Switzerland, Germany, Denmark and 
France. The firms distribute products such as cardiac valves and devices for hemodynamic 
monitoring, products for cardiac surgery, supply and delivery of hearing aids, orthopaedic 
implants, and pharmaceuticals and chemicals. The know-how that is important for the 
successful distribution of medical devices is knowledge of the product, sales competencies 
such as ability to bridge medical, technical and economic knowledge of the healthcare system, 
and maintenance of customer relationships over time.  
 
3.3 Characteristics of sample firms 
The findings in our interview survey suggest that there are important differences between the 
ways in which global technology and production changes affect firm performance and 
innovation in the four groups (see Table 1 below). This section briefly discusses general 
economic characteristics of the four groups of firms, before the analysing their knowledge 
bases and innovation activities in section 4. Group A firms are rather small (on average 14 
employees), whereas Groups B and C also have some larger firms. Despite their small size, 
Group A firms have a higher percentage of international sales, and have the highest 
percentage of new-to-market innovations, i.e. they are more innovative and relatively more 
oriented to external markets, although they still sell almost 80% within Austria. 
 
Table 1: Selected indicators by group 
 Number 
of firms 
Number of 
employees 
(2015) 
Change in 
employees 
since 2010 
(% of firms) 
International 
sales in 2015  
 
(% of total sales)  
Innovation  
new-to- market 
since 2010  
(% of firms) 
Group A 11 147 17.7 21.3 90.9 
Group B 9 587 22.8 16.7 77.8 
Group C 5 4037 12.6 14.0 60.0 
Group D 5* 73 8.2 0** N/A 
*This is not the total number of sales firms in the firm population. For all the other groups, the firms in our 
sample represent about 90% of all the firms in the respective population.  
**Group D firms located in Vienna in order to access the Austrian market and therefore typically do not sell 
internationally.  
 
                                                 
4 Statistics obtained from the AURELIA database of firms in Austria in 2014.  
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Furthermore, technology intensive Group A and B are engaged in areas at earlier stages of the 
industry life cycle and have experienced a higher employment growth in the last five years, 
whereas the more mature and less technology intensive Group C and Group D (the sales and 
trade firms) grew less in comparison. However, the growth rates of all groups show that 
production and demand for medical devices is growing overall, i.e. the medical devices sector 
is a dynamic one in general. The high number of employees in Group C, however, indicates a 
mature segment with large firms, a lower rate of new-to-market innovation, and more 
stability. Groups A and B, in contrast, represent younger and more dynamic segments of the 
sector that are combining technologies such as mechanical and electronic technologies with 
new technology areas such as ICTs and software. The high level of new-to-market 
innovations in Groups A and B further indicates a technologically dynamic segment in which 
capabilities to combine internal and external knowledge exist as well as conditions to exploit 
such new knowledge. In addition to firm characteristics and performance, a central focus of 
our research lay in the local factors that make Vienna attractive for firm foundation (see the 
following section).  
3.4 Local factors important for firm foundation in Vienna 
Firms rely upon a variety of local factors and conditions to set up a firm in a region and to 
stay there. An important question in our research was thus to understand why the medical 
devices firms had decided to choose Vienna for their location, and whether these factors 
remained important over time to keep the firms there. Figure 2 below shows, for Groups A to 
C5, the importance of different factors for the foundation of the firm in Vienna (as opposed to 
elsewhere), and for remaining in Vienna later on. For all three groups of firms, personal 
reasons (for example, that the founders already lived there, that they had studied there, and 
that their family and friends were there) were the most important factors for founding the firm 
in Vienna. This finding is in line with other location studies that also often have shown a high 
importance of personal factors for the location of firms. These personal factors remained 
consistently of high importance also for staying in the region for all groups. In Group A in 
particular, the importance that the founder had studied in Vienna, and that his/her cooperation 
partners were former fellow students at the same university, was raised as a key reason for 
setting up the firm in Vienna. 
There are differences across the groups in terms of the other factors to locate and remain. For 
Group A location factors, universities and research institutes were second most important, and 
third came local qualifications and skills. The universities were important especially for firms 
set up by persons who had graduated and still had links to other university staff. The top three 
reasons for staying in the region are the same as the factors for setting up the firm there. This 
indicates that personal factors remain highly important, but also that the firms continue to 
mirror the competencies of the universities and the local labour pool. In contrast, local 
demand was the second most important factor for locating the firm in the region for Group B 
firms.  
                                                 
5 Group D firms (not depicted here) are all subsidiaries and were located in Vienna to directly access the 
Austrian market. 
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Figure 2: Importance of Vienna factors for founding the firm  
and for staying in the region  
Group A: High-tech non-invasive diagnostics and monitoring devices (n=11) 
 
Group B: High-tech invasive prosthetics, mechanical and robotic devices (n=9) 
 
Group C: Low-tech products (n=5) 
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Over time, universities and research institutes became more important than previously, for 
staying in the region. For Group C (low technology) firms, personal reasons and local demand 
were highly important, and more so than for all other firms (rated 4 or 5). Group C contains 
firms that are relatively older, and the high importance of personal reasons and local demand 
indicated that these sets of factors are indeed key in embedding these firms in Vienna. The 
next chapter presents the analysis of the factors and processes that underpin the 
developmental changes of the firms. 
 
4. Factors for growth and development of the firms and the cluster 
 
Which factors did companies regard as most important for driving firm- and cluster 
development? And how did these factors change in the past 5 years? Section 4 investigates 
such factors and processes that underpin the development of the medical devices firms in 
Vienna from a multi-scale perspective and for two points in time. In 4.1 we investigate the 
perceived importance of economic and institutional factors (such as qualifications and skills, 
demand, and financial capital, regulation, and universities and research institutes) in the 
Vienna region, in Austria and at the international scale across the four groups of firms. In 4.2, 
we will focus on factors for development at the cluster level (4.2).  
 
4.1 Factors for firm development 
There are some important differences between the investigated firm groups in this respect. For 
the technology intensive Groups A and B we find that a highly qualified labour force as well 
as universities and research organisations are of key importance (figures 3-4). For low-
technology firms, rather the access to clients (demand) and the role of networks matter most 
strongly (Figure 5).  
 
Looking more closely to the driving factors for Group A firms (high-tech non-invasive 
diagnostics and monitoring device: figure 3) we can see that the availability of qualified 
people and access to universities and research organisations matter strongly at the regional 
level. Also, Group A firms benefited most from local and national STI policies in form of 
subsidies for high-tech firms and products. As regards clients and suppliers it is the 
international level that is most important and of an increasing relevance. These firms, thus, 
rely strongly on the regional and the Austrian talent and knowledge assets for innovation and 
qualified production as well as on respective subsidies, but they also link up into large-scale 
value chains as regards suppliers and clients. Regulations at the regional levels were 
considered unimportant, because the regulatory framework for these companies is at the 
national and EU levels. The importance of international relations has been clearly increasing 
in the past years, and the same networks (which are more durable relations and 
collaborations).  
 
Group B firms (high-tech invasive prosthetics, mechanical and robotic devices: figure 4) share 
the reliance on local skills and qualifications with Group A firms. Universities and research 
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organisations from the region, however, were less relevant for them. Universities as well as 
regulations became relevant only recently, but on an international scale. Obviously, local 
universities and research organisations could not offer the kind of specialised knowledge that 
those companies needed for innovating. In terms of markets and clients, they are more 
oriented to the regional and Austrian market in comparison, and this applies also to suppliers 
and supporting services.  
 
The pattern for the low-technology product firms contrasts sharply (Group C: figure 5). The 
two key factors for these firms are regional and Austrian clients (i.e. the health system, 
hospital and doctors) as well as regional and national networks for opening up these markets. 
Over time we see, however, an increase of the skill-  and knowledge factors (universities and 
research), mostly on the Austrian scale. It seems that these companies are strongly oriented to 
the Austrian market for medical products and also relying on respective qualifications and 
competencies at the national level. All international factors were previously unimportant, and 
some increased in importance over time. In particular, international regulations and networks 
have become more relevant (in particular EU-level regulation). Indeed, the biggest shift for 
these firms over time occurred in the international institutional dimension.  
 
For medical devices distribution and sales firms (Group D firms: figure 6), unsurprisingly 
access to the Austrian health market and supporting firms matters strongly, as well as 
networks to open up these markets. Furthermore, the availability of qualified labour and skills 
on the regional and Austrian labour market is important. Previously, international factors were 
unimportant, but almost all factors gained in importance internationally over time. This might 
be due to an increasing relevance of European regulations and directives, as well as various 
kinds of European and global networks.  
 
When comparing the results across groups, we find that Group A firms were previously 
intensively engaged at the regional level (four out of the nine factors were considered 
important), and internationally (where five out of nine factors were considered important). For 
all four groups the biggest shift occurred in the importance of international factors, and in 
particular regulations, over time. The Low-tech firms are strongly oriented to the Austrian 
market for medical products, relying also on respective competencies and skills. The 
importance of skills at the national level is most important for Group D firms, at least partially 
because of the importance of local and national knowledge for sales (intersection between 
technical knowledge and customer knowledge of doctor and hospital needs). 
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Figure 3: Regional, national and international factors important for firm development 
Group A: High-tech non-invasive diagnostics and monitoring devices (n=11) 
 
Previously6  
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6 Previously denoted about three to five years ago, and presently represented the time of the interviews, which 
took place in 2015. 
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  Figure 4: Regional, national and international factors important for firm development:  
Group B: High-tech invasive prosthetics, mechanical and robotic devices (n=9) 
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Figure 5: Regional, national and international factors important for firm development 
Group C: Low-tech products (n=5) 
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Figure 6: Regional, national and international factors important for firm development 
Group D: Medical devices distribution and sales firms (n=5) 
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4.2 Factors for cluster development 
Firms also benefit from a suitable environment at the meso-level of the cluster or sector. 
These conditions may differ from those at the firm level, since they are more indirect to the 
firms and because they might show a higher stability than those of the firms. The cluster may 
benefit also other firms and make it easier to create new firms. However, each technology 
sub-area may have different perceptions of cluster factor conditions that are important for 
growth. The empirical findings show that the factors for cluster development differ from the 
company factors in several respects. The distinctive profiles of factors for the groups A-D 
seem to get lost, i.e. the companies see more or less all factors as relevant for cluster 
development, whereas there were clear distinctions at the firm level. What is similar to the 
firm level perspective is the increasing importance of the international scale for all firm 
groups. For the technology-intensive Group A and B firms this applies to all investigated 
factors, and for Group C and D firms in particular for regulations and networks. Group D 
firms emphasise the high importance of the national level (i.e. the Austrian health system) 
also at the cluster level. 
 
For Group A firms (high-tech non-invasive diagnostics and monitoring devices: Figure 7), 
subsidies, followed by networks, universities and research institutes and skilled people, were 
considered important regional factors for cluster development. Less important at the regional 
level were directives and regulations, which is due to the fact that the regulatory framework 
for this sector is mainly defined at the EU and national, not the regional levels). Regional 
factors either remained stable in their importance for the cluster, or declined somewhat (skills 
and subsidies). At the national scale, all factors were considered important for the cluster, 
especially qualifications and skills. Over time, we can observe a marked increase of 
importance of all factors including demand, networks, talent, and financial capital at the 
international scale. 
 
The picture of cluster factors for Group B firms (high-tech invasive prosthetics, mechanical 
and robotic devices) differs from Group A since most of the regional and national factors 
were less important in comparison except the universities and research. The latter finding 
contrasts to the micro (firm-) results and indicates that companies see an important role for 
Vienna and Austrian based knowledge providers for the overall cluster but not directly for 
their firm. Similar to Group A firms we can observe that all international factors have gained 
in importance for the cluster also according to Group B firms, especially international 
regulations, skills, universities and research institutes, demand and supporting firms.  
 
29 
 
 
 
Figure 7: Regional, national and international factors important for cluster development 
Group A (high-tech non-invasive diagnostics and monitoring devices) (n=11) 
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Figure 8: Regional, national and international factors important for cluster development 
Group B (High-tech invasive prosthetics, mechanical and robotic devices) (n=9) 
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For Group C firms (low-tech products) regional and national cluster factors were important in 
particular for qualified labour, universities, networks and demand, while these two levels had 
no relevance for the sourcing of financial capital. As regards regulations, the cluster is seen to 
depend on national and international rules and directives. Over time, we observe an increase 
of cluster factors on all three scales in particular for the competence- and knowledge related 
factors (qualifications, universities and research). This is to some extent unexpected for the 
low-tech firms and contrasts to the micro (firm-based) results. It implies that companies see 
an important role for competencies and knowledge for the overall cluster even if these factors 
are regarded as less relevant for their firms. 
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Figure 9: Regional, national and international factors important for cluster development 
Group C (Low tech products) (n=5) 
 
Previously 
 
Presently 
 
Group D (sales and distribution) firms considered regional level universities and research 
institutes, demand and local skills as most important for the cluster. At the national level, 
skills, regulations and directives were evaluated as most important for the cluster. Over time, 
we observe a shrinking importance of the region for most cluster factors, whereas the national 
level has gained importance for knowledge organisations (universities and research) and 
demand, in addition to the already important qualifications and regulations. The international 
level has gained in importance for the cluster over time for regulation, networks and financial 
capital.  
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Figure 10: Regional, national and international factors important for cluster 
development: Group D (Sales and distribution firms) (n=5) 
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5. Knowledge bases and innovation  
 
This chapter focuses on knowledge bases and competencies for innovation in the firms. 
Guided by the literature on innovation and knowledge flows, the interview questions were 
directed towards knowledge processes “inside” the firm, and “outside” the firm. Although 
these two ‘bodies of knowledge’ are of course inseparable, the literature suggests that they 
rely upon somewhat different embodiments, mechanisms and patterns of knowledge creation, 
and inform different types of policies. The first part of this chapter discusses the knowledge 
bases internal to the firm, such as competencies embodied in people and in innovation-
relevant activities. Second, the chapter presents the results on external knowledge sources, 
such as different types of interactions and collaborations, and their characteristics such as 
their duration and intensity.  
 
5.1 Internal firm competencies 
Firm competencies are made-up of skills, routines, practices and tasks that the firms engage in 
in order to bring forward innovations. In this research, we focused on competencies specific 
to the medical devices industry to gain insight into micro level dimensions of knowledge base 
creation. The tables below suggest that the predominant knowledge base in the medical 
devices cluster is represented by the synthetic category, and second by the analytic knowledge 
base. In comparison, the groups differ somewhat as to which knowledge types are important. 
For Group A and Group B firms, the combined synthetic-analytic knowledge base seems to be 
the most important. Synthetic knowledge is most important also for Group C firms, whereas 
these firms are less relying on analytic knowledge (scientific know how).  
 
Table 2: Firm competencies (average importance on 1-5 Likert-scale) 
Group A: High-tech non-invasive diagnostics and monitoring devices (n=11) 
 Previously  
(5 years ago) 
Presently Change 
High-skilled employees 4.64 4.73 0.09 
Scientific know-how 4.64 4.73 0.09 
Technical know-how 4.64 4.82 0.18 
Creativity and design 4.45 4.64 0.19 
Marketing 1.64 4.55 2.91 
Organising and logistics 3.91 4.27 0.36 
Product and process development 4.36 4.55 0.19 
Manufacturing know-how 3.45 3.73 0.28 
 
Group A firms (high-tech non-invasive diagnostics and monitoring devices) place a very high 
importance on high-level skills, and scientific and technical knowledge, as well as creativity 
and design know how. Over time, the importance of all types of skills increased. In particular, 
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the importance of marketing know how increased by far to the largest degree than all other 
types of knowledge. This indicates an increased importance of knowledge how to penetrate 
the market, contact with medical practitioners, and how to market the product globally. A 
high-level of skills, scientific knowledge and technical Know-how remain the most valuable 
knowledge types for this group.  
 
Table 3: Firm competencies (average importance on 1-5 Likert-scale)  
Group B: High-tech invasive prosthetics, mechanical and robotic devices (n=9) 
 Previously  
(5 years ago) 
Presently Change 
High-skilled employees 4.11 4.56 0.45 
Scientific know-how 3.00 3.78 0.78 
Technical know-how 4.22 4.78 0.56 
Creativity and design 3.56 4.22 0.66 
Marketing 2.44 4.11 1.67 
Organising and logistics 3.56 4.33 0.77 
Product and process development 4.11 4.44 0.33 
Manufacturing know-how 3.00 3.56 0.56 
 
Group B firms (high-tech invasive prosthetics, mechanical and robotic devices) also place a 
high level of importance on all types of skills, and the highest importance on technical 
knowhow and high-level skills. The highest importance is given to technical knowledge as 
well as product and process development. Creativity and design is third most important, 
followed by organising and logistics. This group also experienced by far the biggest increase 
in importance for symbolic (creativity, design and marketing) knowledge.  
 
Table 4: Firm competencies: Group C (average importance on 1-5 Likert-scale) 
 Low tech products (n=5) 
 Previously  
(5 years ago) 
Presently Change 
High-skilled employees 3.00 3.80 0.80 
Scientific know-how 1.80 2.80 1.00 
Technical know-how 3.60 3.80 0.20 
Creativity and design 2.80 3.20 0.40 
Marketing 3.00 4.00 1.00 
Organising and logistics 3.20 3.20 0.00 
Product and process development 2.80 3.20 0.40 
Manufacturing know-how 2.60 2.80 0.20 
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Group C (low-tech firms) does not place as much importance on the different types of 
knowledge as Group A and B. This indicates a lower technological intensity, but also a lower 
combinatorial knowledge intensity overall in this group of firms in Vienna. However, in 
relative terms, Group C firms place the highest importance on synthetic and symbolic 
knowledge (technical Know-how and marketing knowledge). The biggest increase in 
importance occurred in marketing knowledge and scientific knowledge for this group, 
however scientific knowledge plays a relatively small role overall. This indicates that for 
these low-tech firms practical knowledge such as technical and organisational Know-how is 
overall most relevant. It is interesting to observe that scientific Know-how has also gained 
importance showing a certain trend towards combining practical and scientific knowledge. 
Similar trends were observed in the literature for other sectors and regions as shown in the 
literature review. 
 
Table 5: Firm competencies (average importance on 1-5 Likert-scale) 
Group D: Sales and distribution firms (n=5) 
 Previously  
(5 years ago) 
Presently Change 
High-skilled employees 4.80 5.00 0.20 
Scientific know-how 3.60 4.60 1.00 
Technical know-how 4.20 4.40 0.20 
Creativity and design 2.80 3.20 0.40 
Marketing 2.40 4.60 2.20 
Organising and logistics 3.80 4.00 0.20 
Product and process development 3.20 3.40 0.20 
Manufacturing know-how 3.00 3.00 0.00 
 
Group D (sales and distribution firms), composed of trading firms, place a high importance on 
high skills in general. Also scientific knowledge and marketing knowledge are important for 
this group. When asked to elaborate on what is meant by ‘high-skills’, these firms responded 
that the types of skills that are required are business skills and technical understanding of the 
product that is being sold. These two types of knowledge are essential when selling to a 
competitive market such as the healthcare sector. Similar to all the other groups, the firms in 
this group also experienced the largest increase in importance of marketing knowledge.  
 
5.2 External knowledge flows: Innovation cooperation 
Knowledge accumulation and innovation is supported by relationships that firms have with 
other organisations. The tables below present information on Groups A, B and C (Group D is 
excluded because innovation is less relevant for these sales and distribution firms). The results 
are presented as the numbers of collaborations that the firms of each group have with different 
types of innovation partners (suppliers, clients, competitors, firms from the same sector, firms 
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from a different sector, universities, and public sector agencies) at different spatial scales. 
Some of the interviewed firms listed all of their innovation partners, others (particularly the 
larger firms) indicated only their most important ones. Another fact that should be taken into 
account is that some of the numbers result from only few responses.  
 
Table 6: Cooperation partners for innovation by partner type and location 
(Number of responding firms = 8, multiple responses possible) 
Group A: High-tech non-invasive diagnostics and monitoring devices 
 
 Vienna  National EU  Global Total 
Supplier 2 1 3 2 8 
Client 2 3 5 1 11 
Competitor 0 0 1 1 2 
Firm from same sector 0 1 0 1 2 
Firm from different sector 0 1 0 0 1 
University 9 6 2 2 19 
Public sector agency 2 0 0 1 3 
Total 15 12 11 8 46 
 
 
Table 7: Cooperation partners for innovation by partner type and location  
(Number of responding firms = 9, multiple responses possible) 
Group B: High-tech invasive prosthetics, mechanical and robotic devices 
 Vienna  National EU  Global Total 
Supplier 2 0 4 0 6 
Client 5 7 2 2 16 
Competitor 0 0 0 0 0 
Firm from same sector 0 1 1 0 2 
Firm from different sector 0 0 0 0 0 
University 6 3 4 1 14 
Public sector agency 0 0 0 0 0 
Total 13 11 11 3 38 
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Table 8: Cooperation partners for innovation by partner type and location  
(Number of responding firms = 4, multiple responses possible)  
Group C: Low tech products 
 Vienna  National EU  Global Total 
Supplier 0 0 3 1 4 
Client 2 7 0 0 9 
Competitor 0 1 0 0 1 
Firm from same sector 1 0 0 0 1 
Firm from different sector 0 0 0 0 0 
University 1 2 0 0 3 
Public sector agency 0 0 0 0 0 
Total 4 10 3 1 18 
 
Comparing the results for these groups we can observe that the most active group in terms of 
innovation cooperation is Group A specialised in High-tech non-invasive diagnostics and 
monitoring devices. The 8 responding firms indicate overall 46 innovation cooperations, 
whereas the 9 Group B firms have 37 and the 4 Group C firms have 18. As regards the pattern 
of cooperation, Groups A and B share certain features: The main innovation partners are 
universities & research organisations as well as clients that are most often at the regional and 
national levels (i.e. from the RIS and NIS). Clients and suppliers as innovation partners are 
more often located at the national (e.g. Austrian hospitals) and European scale. Group A firms 
are most strongly relying on university partners (19 out of 46). Obviously, the research profile 
of Viennese and Austrian universities fits the needs of these Non-invasive diagnostics and 
monitoring devices firms quite well. Group B firms (High tech invasive prosthetics, 
mechanical and robotic devices) have clients from the region and Austria as predominant 
partner type for innovation. It seems that this type of firms relies more on knowledge from the 
users (hospitals and doctors) for improving the products and services or for developing new 
ones. As to be expected, for Group C firms (Low technology products) universities are less 
relevant in comparison (only 3 out of 18 cooperations). These firms rely even more on clients 
and users from the Austrian health system as innovation partners. Less relevant as innovation 
partners for the medical devices firms are other firms from the sector and beyond including 
competitors, as well as public sector agencies that are active in various kinds of support.  
Regarding the spatial orientation, it is obvious that the region and the country are the 
predominant levels of innovation interactions, whereas the global level is less relevant in 
general. The regional- and country focus in innovation relationships is stronger for this sector 
than e.g. for ICT, biotech or automotives (see Tödtling et al. 2006, Trippl et al. 2009). This 
finding can be explained by the important role of local research hospitals and medical 
universities as well users for knowledge generation and innovation in this sector (see the 
literature review in section 2). 
 
  
38 
 
Duration of collaborations 
Group A firms had the longest during cooperations with suppliers in Vienna and in the EU. 
This fact might be explained by the ways in which products in this group of firms are 
produced, and that inputs from suppliers often have to be changed and adjusted to fit the client 
requirements. Furthermore, it is not surprising that in this sector which is highly dependent 
upon knowledge produced in the process of application, clients are the second group in which 
cooperation last relatively long (between 2 and 6.25 years on average). Also for this type of 
cooperation partner, the region is more important than for any other, followed by the national 
level. The third longest cooperation is with universities, of which collaborations with 
Viennese universities last the longest, followed by  other universities at the national level.  
 
Group B firms have longer during cooperations with suppliers, clients and universities, than 
with other organisations. The longest cooperation in this group, different from Group A, is 
that with local and national universities. Second longest are collaborations with EU suppliers, 
followed by those with regional and national clients. The long duration of collaborations with 
universities such as medical universities and teaching hospitals, are necessary because it takes 
a long time to test the products. Group C firms have the longest cooperation with external 
partners overall, and especially with local and national clients, and with EU suppliers. This 
group has a higher proportion of older firms, which partially explains the long cooperation 
times. Cooperation with universities is third longest, with local universities and national 
universities being the main cooperation partners.  
 
Intensity of collaborations 
Group A firms have the highest level of intensity of collaborations with suppliers, clients and 
universities at all levels. As such, the intensity of collaborations mirror quite closely their 
duration, which is to be expected. The highest numbers of responses are for clients and 
universities. For these types of partners, the most important functions involved are use and 
application. Universities are often consulted because they have access to hospitals where the 
products can be tested (not because of the scientific knowledge base, for pharma-biotech).  
 
Group B has the highest intensity of collaboration with clients at regional, national and EU 
levels. The intensity of innovation interactions with suppliers at the EU level is slightly higher 
than for Group A firms, indicating a higher EU focus of Group B firms in this regard. Group 
B firms also have a high intensity of innovation cooperation with EU universities, and second 
with Austrian universities. The high degree of specialisation in this group is an important 
driver for building intensive collaborations with such knowledge organisations beyond the 
region. Group C firms also have relatively intense collaborations with suppliers, clients, and 
universities, although the number of such collaborations is lower than for Group A and B 
firms. As was already stated, Group C firms are older, and this is also true for their innovation 
collaborations. The combination of these features signals a certain danger for functional and 
cognitive “lock-in” (Grabher 1993, Hassink and Shin 2005), since these firms are engaged 
intensively with the same partners for a long time.  
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Our findings on knowledge bases and innovation show that firms in all four groups are all 
quite similar in their dependency on high-level skills and in particular technical skills. The 
main differences between the groups are the higher reliance of Group A firms on scientific 
knowledge internal to the firm, and the lower high-skilled and combinatorial knowledge 
intensity of Group C firms. For all firms, having in-house marketing knowledge has increased 
in importance over time, both for accessing the local, and increasingly the global market. 
Regarding external knowledge interactions of firms we observe that the most important actors 
for knowledge sourcing and innovation collaboration for all groups of firms are universities 
and research institutes, an important mechanism for the creation of the synthetic-analytic 
knowledge base. However, there are some differences between the groups of firms, in the type 
of network partner and the duration and intensity of these collaborations: Group A firms 
cooperate most with actors in Vienna, specifically universities and research institutes than 
with any other type of organisation. Second most important are clients, and then suppliers, 
located in Austria and internationally. Group B creates more specialised products, so national 
clients play a bigger role than local clients. Similarly, for Group C firms clients at the regional 
and national levels are most important, whereas they are less dependent on the science base 
than the two other groups. 
 
 
6. Policies and regulations  
 
This chapter deals with policies and regulations at regional, national and European scales 
relevant for the medical devices sector in Vienna. Some of these policies seem to have a more 
direct impact. Others take effect more indirectly depending on the spatial scale on which they 
are implemented. Furthermore, the role of policies varies between groups of firms within the 
cluster. These groups differ with regard to the technologies used as well as with regard to their 
knowledge bases and –flows. Typically, cluster firms rely upon knowledge networks and -
flows on multiple spatial scales (Strambach and Klement, 2012). This makes them also 
dependent on policy settings on these different levels. In the following we examine med-tech 
relevant policies and regulations on regional, national and European levels. Then we 
investigate the role of policies for the development of the different firm groups in the medical 
device cluster in Vienna.  
 
6.1 Policy frameworks and regulations at different territorial levels 
Policies and regulations relevant for the medical devices sector exist on several geographical 
levels that are often inter-related. Thus, a multitude of policy activities and institutions has 
developed that support but also limit sectoral and cluster development. At higher spatial scale, 
the more general regulatory framework is laid down. At lower levels, policy activities tend be 
more specific and targeted to promote sector growth, performance and innovation within 
regions and clusters. The complexity of policy settings becomes apparent in the formulation 
and implementation of such policy activities. There is an unclear division of responsibilities 
between member states and European legislation, and the various participants in the policy 
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formulation process often have conflicting interests (Kent et al., 2006). Which policy settings 
and regulations relevant for the medical device cluster in Vienna can we identify at different 
spatial scales?  
 
European level 
Regulations and directives at the European level matter considerably for the medical devices 
sector. Medical device regulations share a number of characteristics with other knowledge-
based sectors. They evolved over time, are multi-faceted, intersect with other sectors, and are 
not expressed in one single EU directive (Altenstetter, 2003). They provide a uniform 
definition for medical devices within the European Union, and aim at a higher transparency 
and a better coordination and communication of market surveillance activities (Schreyoegg et 
al., 2009). The EU regulation on medical devices is based on the general policy on the single 
market and three specific medical devices directives: The directive on medical devices (MDD, 
93/42/42/EEC) aims at harmonizing laws that are related to medical devices on the European 
level. The directive on active implantable medical devices (AIMD, 90/385/EEC) regulates the 
market readiness and service parameters for AIMDs. The in vitro diagnostic devices directive 
(IVDD, 98/79/EC) regulates the performance, safety and quality of in vitro diagnostic devices 
in the European Union (Altenstetter, 2003).  
 
The uniform regulation of medical devices at the European level brings forth both advantages 
and disadvantages. On the one hand, it is expected that transnational market opportunities 
grow in situations where such standards are not yet met (WHO, 2003). More importantly, the 
safety and performance of medical devices and the competitiveness of respective companies 
are expected to rise. On the other hand, the harmonization of standards across the European 
Union exposes the firms of some countries to stronger international competition. Moreover, 
different national interests have often slowed down the formulation and implementation of 
policy activities. For example, the delay of almost eight years in adopting the IVDD was 
largely due to diverging interests between the European Union, France, Germany and the 
United Kingdom (Altenstetter, 2003).  
 
The medical devices sector is also affected by the European Union’s objective to promote 
competitiveness and growth. In its strategy for Europe 2020 the European Union has 
formulated three interdependent priorities in this regard. “Intelligent growth” should promote 
growth within the EU based on knowledge and innovation, “sustainable growth” supports 
activities that use resources in a responsible way, and “integrative growth” aims at stimulating 
employment growth as well as social and territorial cohesion (EC, 2010). The strategy for 
Europe 2020 has also relevance for the medical device sector. It is suggested that knowledge 
and innovations should be increased by means of enhancing the quality of education, raising 
the research performance, stimulating knowledge transfers, adopting ICTs, and supporting 
marketability of innovative ideas (EC, 2010). 
 
Some policy activities are more specific with regard to medical devices. The key initiative 
“Innovation Union”, for example, has a strong focus on health- and demographic related 
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challenges. The initiative seeks to stimulate private R&D investments in this area by 
reforming patent regulation, facilitating access to venture capital and providing unrestricted 
access to demand-side policies such as public procurement (EC, 2010). Policy instruments 
that have been already established in the EU should be reformulated in order to support those 
aims and stakeholders (research organisations, SMEs, etc.) that were neglected before (EC, 
2010).  
 
National level 
National governments also have considerable power in directing the medical device sector. 
Whereas the EU regulations and directives directly or indirectly related to medical devices 
sector provide the general regulatory frame, it is the national institutions that translate these 
directives into national law and regulations. This may cause differing routes and 
interpretations of European directives. Three distinct kinds of organisations are responsible 
for implementation of regulations at the national level. First, state-based competent authorities 
are responsible for their oversight, enforcement and compliance. Second, there are notified 
bodies that overlook certification processes and conduct formal audits of medical devices. 
Third, manufacturers are obliged to inform the competent authorities of any incidents that 
arise from malfunctioning of any medical device (Altenstetter, 2003). 
 
In Austria, the three European directives on medical devices are implemented in the Medical 
Products Law (MPG) and the Medical Devices Marketing Regulation (MPBV) in which the 
use of medical devices in Austrian health-care organisations is settled. Moreover, medical 
device companies that are located in Austria have to register new products at the Austrian 
Federal Institute for Health before the market launch. An example put forward by the Austrian 
Life Sciences study 2012 conducted by AWS (2011) is the e-health initiative of the European 
Union that resulted in the conception of the Austrian Electronic Healthcare Record project 
(ELGA). On basis of this project, each patient in Austria will have the opportunity to review 
personal medical data and provide it to the attending doctors. Policy actors not only expect an 
increase of transparency and more efficient therapy concepts but also a more cost-efficient 
healthcare system (AWS, 2011). 
 
National policies have the advantage to take account of country-specific conditions that might 
be hard to grasp on international or European levels. National policies apart from regulations 
and standards tend to be more systemically organised in order to take account of different 
interests and needs of stakeholders directly or indirectly affected by policy decisions (WHO, 
2003). These policy instruments often support networking, provide a learning platform or help 
firms to get returns on their investments (Smits and Kuhlmann, 2004). In contrast to 
regulations and standards, they often do not require a lengthy legal process of policy 
formulation, implementation or amendment (WHO, 2003).  
 
The use of policy instruments in Austria is influenced by estimations of future growth 
potentials. Areas of medical devices that are expected to grow are mainly linked to 
demographic changes and the aging of society. Consequently, AWS (2011) expects an 
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increase in demand for orthopaedic devices, dental implants or cardiological products, 
ophthalmology, diagnostic systems as well as rehab equipment. The development of the 
medical devices sector also depends on funding and financial support. Public funding has an 
important role in financing medical activities in Austria and is decisive for their growth and 
innovation performance. With about 13% of total funding, public authorities are the second 
most important capital provider. Nevertheless, they range far behind traditional banking 
credits that amount to almost 70% of risk capital. Public financial support relevant for the 
medical device sector is organised by the Austrian federal promotional bank, or the Austria 
Wirtschaftsservice GmbH (AWS). It assists companies to implement innovative projects by 
granting loans, awarding subsidies or issuing guarantees at favourable interest rates. In 
addition, it provides support in the form of specific information, advisory- and other services 
to prospective, established and expanding companies (AWS, 2015). Other important funding 
organisations are the Austrian Research Promotion Agency (FFG) that offers a range of 
services to Austrian companies in the field of applied research and development and the 
Austrian Science Fund (FWF) which funds basic academic research in Austria (LISA Vienna, 
2015).  
 
The “Austria Wirtschaftsservice GmbH” has established a support program for start-ups in the 
life science sector. Life Science Austria (LISA) serves the whole spectrum from the business 
plan to financial and managerial support (LISA Vienna, 2015). Moreover, it represents the 
medical device sector internationally and assists respective companies to move abroad. It 
closely collaborates with regional cluster initiatives such as ECOPLUS (Lower Austria), the 
Health cluster (Upper Austria), LISA Vienna Region (Vienna), Human Technology Styria 
(Styria) and the Standortagentur Tyrol (Tyrol) which aim at enhancing regional network 
structures.  
 
Regional level 
Life sciences and medical devices are central pillars of Vienna’s science, technology and 
innovation (STI) policy (Stadt Wien, 2004; ZIT, 2013; www.wiendenktzukunft.at, 
www.wienwin.at). More than a third of R&D funding is provided by the public sector of 
which only ten per cent come from the City of Vienna. A major share is financed by the 
national government because most of the public research organisations and universities in 
Vienna remain under national responsibility (wiendenktzukunft.at). In 2014 the life science 
sector in Vienna was able to attract 97 million euros from national and regional funding 
agencies (LISA Vienna, 2015). 
 
Despite their limited access to financial resources policy actors at the regional level have 
become more actively involved in supporting firm- and industry development. Since the early 
1990s several policy initiatives have led to the foundation of new public institutions such as 
the ZIT – Technology Agency of the City of Vienna, the Vienna Science and Technolgy Fund 
(WWTF) or DEPARTURE – the Creative Agency of the City of Vienna. One of the main 
objectives was to enhance Vienna’s economic infrastructure in order to attract external 
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knowledge and capital to the region. Therefore, these institutions have a strong focus on 
flexible funding programmes and projects.  
 
A particularly strong focus is on the support of SMEs that tends to be less considered by 
policies on the national and European level. This includes measures for a better access to 
applied research funding and other R&D activities. Also, there have been attempts to promote 
specific technologies in the Vienna region. Cluster initiatives such as LISA Vienna or the 
Automotive Cluster Vienna Region (ACVR) have been established in order to attract foreign 
direct investments to the region. The Vienna Business Agency, the Vienna Science and 
Technology Fund (WWTF) and the INiTS business incubator are among the most important 
policy institutions at the regional level. The first is particularly important for national and 
international companies to get a variety of business and development support including 
funding, consulting and innovation support (viennabusinessagency.at). The Vienna Science 
and Technology Fund (WWTF) also has an important role for medical devices because it 
attracts promising young researchers from abroad and, thereby, enhances the locational 
attraction for foreign direct investments in Vienna. The INiTS business incubator adds to the 
support programs of the Vienna Business Agency and the WWTF. It helps entrepreneurs to 
turn their ideas into a successful business. INiTS provides managerial advice, access to 
venture capital and to international business network.  
 
 6.2 Relevance of policies for firm development  
As we have demonstrated, medical device firms are affected by policies at these different 
levels. While the ones at the European level are usually of a more general nature, policies at 
lower spatial scales become more concrete and policy actors more actively involved in the 
market and the industry. The findings from our company interviews show that policies in 
general matter, but they matter differently for the types of firms in the cluster. In our 
interviews firms were asked about the role of policy for their foundation as well as their 
further development. Overall, they gave the impression that policies are relevant and that the 
importance of policies rises as firms develop. While only 40% of the firms interviewed 
consider policies to be directly or indirectly relevant for their foundation, there is a tendency 
for policies to become more important over time (table 9). However, this is not true for non-
invasive firms (Group A) that consider policies to be more relevant in the founding stage, 
whereas invasive and low-tech firms see a stronger role of public activities in later stages. 
 
Table 9: The relevance of policies in general by firm group  
 Non-invasive 
(n=11) 
Invasive  
(n=9) 
Low-tech 
(n=5) 
Trading  
(n=5) 
Overall  
(n=30) 
Policy relevant for firm 
foundation 
72.8% 22.2% 20% 20% 40% 
Policy relevant for firm 
development 
54.5% 55.6% 60% 20% 50% 
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Table 10 below features policy activities that medical device firms consider important for 
their development in greater detail. Regulations and standards as well as subsidies and public 
funding are regarded as most important overall. 
 
Table 10: The relevance of specific policy areas by firm group 
 Non-invasive 
(n=11) 
Invasive  
(n=9) 
Low-tech  
(n=5) 
Trading  
(n=5) 
Overall  
(n=30) 
Awards, enhancing visibility 9.1% 0% 0% 0% 3.3% 
Subsidies and Funding 72.7% 33.3% 20% 0% 40% 
Cluster organisation & networks 9.1% 0% 40% 0% 10% 
Regulations and standards 36.4% 55.6% 40% 40% 43.3% 
Public procurement, public 
clients, business partner 
9.1% 22.2% 20% 0% 13.3% 
Internationalisation, business 
facilitator 
18.2% 0% 0% 0% 6.7% 
 
However, the results for the firm groups differ substantially. Non-invasive firms, for example, 
rely heavily on subsidies and public funding and indicate a greater variety of policy activities 
to have a role for their development. Particular reasons might be the strong R&D and capital 
intensity for creating non-invasive devices, and a highly competitive market. By contrast, 
invasive and low-tech firms consider a particular strong role for regulations and standards and 
a relatively high relevance of public procurement and public firms as business partners. This 
might be due to the fact, that invasive firms depend strongly on the regulatory setting and the 
demand of the public sector (hospitals). Low-tech companies, moreover, regard cluster 
organisations to be highly important for their development, whereas other firm groups rely 
less on cluster organisations, since they see a risk in revealing business secrets to their 
competitors. For trading firms only regulations and standards are important, as these are often 
country-specific and need to be taken into account for selling their products in Austria. 
Companies were also asked to what extent policies were changing over time in their nature or 
in their importance. 
 
Table 11: Change of policy relevance by firm group 
 Non-invasive 
(n=10) 
Invasive  
(n=9) 
Low-tech  
(n=4) 
Trading  
(n=4) 
Overall  
(n=27) 
Getting more important 20% 33.3% 25% 25% 25.9% 
Getting less important 10% 0% 0% 0% 3.7% 
No changes 30% 33.3% 50% 75% 40.7% 
Getting stricter, tighter 20% 33.3% 25% 0% 22.2% 
Shifting to higher levels 20% 0% 0% 0% 7.4% 
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Overall, there seems to be certain stability in the policy setting since 41% of the interviewed 
firms reported no changes. There was more stability in the policy landscape in particular for 
the trading firms (75%) and the low-tech firms (50%). For the technology intensive Groups A 
and B there is more change in the policy setting. This is particularly true for the invasive 
Group B where 33% saw an increasing importance of policies and further 33% reported that 
regulations have become stricter. Obviously, the high complexity of some of their products 
makes technological and medical requirements and regulations more important for them. 
 
The medical devices firms were also asked on which spatial scales policies had an influence 
on firm- and cluster development. Multiple selections were possible: 
 
Table 12: The relevance of policies on different spatial scales by firm group 
 Non-invasive 
(n=11) 
Invasive  
(n=7) 
Low-tech 
(n=2) 
Trading  
(n=4) 
Overall  
(n=24) 
No level 0% 0% 0% 25% 4.2% 
Regional 45.5% 57.1% 0% 0% 37.5% 
National  72.7% 85.7% 50% 50% 70.8% 
International 72.7% 42.9% 50% 50% 58.3% 
 
Generally, policies and regulations at the national and international levels were considered to 
be most important. And this is more so the case for the technology intensive Group A (non-
invasive) and B firms (invasive). At the national level we find important regulations for the 
health sector as well as support structures for the firms such as support for R&D. The 
international scale refers mainly to the European were also important regulations and 
directives exist (see above). Interestingly the regional level was only relevant for these two 
groups of technology intensive firms, and had no relevance for the low-tech and the trading 
firms. Their reliance on regional policies might also be due to the focus of regional support 
structures on high-tech products and services. But obviously, policies and regulations have a 
higher relevance for the technology intensive Group A and B firms at all levels including the 
regional one. 
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7  Conclusions 
 
Based on the research presented here, which conclusions can we draw for the field and for 
policies to support the Vienna medical devices sector? We first present a summary of main 
findings and indicate strengths, weaknesses and challenges faced by the firms in this cluster. 
The second part draws policy conclusions based on the research findings.  
 
Main findings 
The medical devices cluster in Vienna has a heterogeneous firm population by age, size and 
technology. We identified firms focusing on high-technology medical devices (Group A: non-
invasive and Group B: invasive), firms active in low-tech medical devices (Group C), and 
sales and distribution firms (Group D). Groups A, B and C together represent over 90% of all 
R&D intensive medical devices firms in Vienna. The firms are highly specialised, innovate 
regularly and employ highly skilled people. Group A firms are most innovative, sell more of 
their products or services abroad than the other firms, and are also more internationally 
networked. Group B have one of the most important global players in prosthetics innovation, 
and other highly specialised firms with steady market growth, and connections to national, 
European and global actors. Together these two groups, because of their combinatorial 
capabilities, carry the highest potential of world-class innovations in the cluster and require 
specific supporting infrastructures in order to prosper and grow.  Group C firms are active in 
low-tech medical devices, tend to be older, and rely upon established local and national sales 
networks. These firms tend to face price-based competition from international firms. Group D 
firms are sales- and distribution firms that are mainly subsidiaries of global firms, and are 
specialised in selling to the Austrian and nearby Eastern European markets. Success in Group 
D is most reliant upon deep understanding the local and national markets and requirements.  
 
The main strengths of the sector are incremental innovation, the reliance on local and national 
networks, and understanding of the domestic market. Although some Groups A and B also 
have radical innovations, most of them and in particular Group C firms mainly perform 
incremental innovation and improvements of existing products. In this process they interact 
with their main clients (hospitals) and with local universities and research organisations. We 
understand this incremental and user-led innovation not as a weakness, but rather as a strength 
and it is globally the norm for this sector (see literature review in section 2). The firms spend 
also many efforts in understanding and meeting national and international regulatory 
environments for their products, which differ greatly across countries. A further strength of 
the sector is the growing local and national demand driven by an aging society and public 
efforts to meet this demand. The high value that Austria places on excellent healthcare is an 
incentive for firms to create innovations that meet high standards similarly as in other highly 
developed countries. This increases also their international cost-efficiency and 
competitiveness. For this purpose, the firms also engage in long-standing collaborations with 
local and national health care organisations and universities, benefitting both types of 
organisations.  
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Although the Vienna medical devices sector has such strengths, there are also weaknesses and 
challenges that need to be addressed. The firms engage in R&D, but their international 
performance is weaker compared to the growth that is enjoyed by other technology-based 
industries in Austria. International networks do exist, but these are sporadic and relatively 
recent, and the firms do not seem to have strategies to improve this situation. Furthermore, the 
proximity of the Austrian market to the German and Swiss markets seems to be both a 
blessing and a curse: a blessing when the firms are doing well, and a disadvantage because of 
the increase in competition from especially German firms on the domestic market which is 
likely to increase in future. A final and related challenge is international regulation and 
marketing (in medical devices these tend to go hand in hand) which is changing rapidly and 
because of the growth of different players (for example, the EU level in addition to the 
national levels) is also becoming more complex to oversee. In light of these findings and 
observations, the City of Vienna needs to focus on supporting the strengths, minimising the 
weaknesses and address the challenges facing the local medical devices sector.  
Policy conclusions 
We can draw the following policy conclusions based on our results. First, innovation policies 
for the sector, such as those being currently endorsed in Vienna and in Austria, need to 
acknowledge the importance of both radical and incremental innovation (and not, as currently, 
radical innovation only). For example, currently Group A firms (which tend to produce such 
radical product innovations) have been the focus of Vienna’s innovation policy, and this could 
be maintained or increased, but just as importantly, the range of government funded R&D 
should be broadened to include technology areas important for Groups B and C respectively.  
 
Second, the knowledge of the domestic health sector is clearly an advantage and a strength of 
these firms, however, this knowledge should not just include which customers to sell to (as it 
tends to do) but which actors in the hospital and medical landscape could be useful partners in 
the innovation process (such as in product testing). The testing stage is highly reliant upon 
doctors’ usage of individual items in their practice, and feedback to the firms that arises from 
this usage benefits from face-to-face interactions with the firm. Policies that are specifically 
designed to support firms in the development and testing phases of their product innovation 
could greatly shorten this phase and increase the success of the product in the market. 
Furthermore, a good reputation of a product in a market with high standards such as Austria is 
an advantage in international marketing of such products.  
 
Third, although some firms manage to navigate international regulatory requirements well, 
this type of knowledge needs to be improved and acquired by all firms in this sector. 
Regulation can be a major barrier to market entry and it is therefore essential that this type of 
knowledge is acknowledged as important for the sector. For example, policy measures could 
be designed for local inter-firm knowledge transfer, and for the inflow of international 
expertise. Furthermore, this knowledge needs to be acquired as early on as possible in the 
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product development stage to avoid additional future costs. The Austrian government could 
support the increase of firm Know-how on the large medical devices markets such as USA 
and Germany, as well as growing markets such as China and India.  
 
Fourth, the Vienna medical sector is locally and nationally much better networked than 
internationally. This situation needs to be improved by specific measures that build firm 
competencies for internationalisation (such as easier recruitment of international high-skilled 
labour, and alliances with international firms such as joint ventures and R&D collaborations). 
Fifth and finally, the highly skilled labour pool needs to be invested in nationally, targeting 
specific technology areas that are required for medical devices innovation such as ICTs, 
mechatronics, and electrical engineering of micro products.  
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